Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Molecules ; 26(12)2021 Jun 17.
Article in English | MEDLINE | ID: mdl-34204472

ABSTRACT

The ostrich oil of Struthio camelus (Ratite) found uses in folk medicine as an anti-inflammatory in eczema and contact dermatitis. The anti-inflammatory effect of a γ-lactone (5-hexyl-3H-furan-2-one) isolated from ostrich oil and its formulated nano-emulsion in formalin-induced paw edema was investigated in this study. Ostrich oil was saponified using a standard procedure; the aqueous residue was fractionated, purified, and characterized as γ-lactone (5-hexyl-3H-furan-2-one) through the interpretation of IR, NMR, and MS analyses. The γ-lactone was formulated as nano-emulsion using methylcellulose (MC) for oral solubilized form. The γ-lactone methylcellulose nanoparticles (γ-lactone-MC-NPs) were characterized for their size, shape, and encapsulation efficiency with a uniform size of 300 nm and 59.9% drug content. The γ-lactone was applied topically, while the formulated nanoparticles (NPs) were administered orally to rats. A non-steroidal anti-inflammatory drug (diclofenac gel) was used as a reference drug for topical use and ibuprofen suspension for oral administration. Edema was measured using the plethysmograph method. Both γ-lactone and γ-lactone-MC-NPs showed reduction of formalin-induced paw edema in rats and proved to be better than the reference drugs; diclofenac gel and ibuprofen emulsion. Histological examination of the skin tissue revealed increased skin thickness with subepidermal edema and mixed inflammatory cellular infiltration, which were significantly reduced by the γ-lactone compared to the positive control (p-value = 0.00013). Diuretic and toxicity studies of oral γ-lactone-MC-NPs were performed. No diuretic activity was observed. However, lethargy, drowsiness, and refusal to feeding observed may limit its oral administration.


Subject(s)
Lactones/isolation & purification , Lactones/pharmacology , Struthioniformes/metabolism , Administration, Oral , Administration, Topical , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Diclofenac/administration & dosage , Diclofenac/pharmacology , Edema/drug therapy , Emulsions/pharmacology , Formaldehyde/adverse effects , Ibuprofen/administration & dosage , Ibuprofen/pharmacology , Male , Palaeognathae/metabolism , Rats , Rats, Wistar , Skin/drug effects
2.
Molecules ; 26(3)2021 Jan 22.
Article in English | MEDLINE | ID: mdl-33499325

ABSTRACT

Zygophyllum coccineum, an edible halophytic plant, is part of the traditional medicine chest in the Mediterranean region for symptomatic relief of diabetes, hypertension, wound healing, burns, infections, and rheumatoid arthritis pain. The current study aimed to characterize Z. coccineum phytoconstituents, and the evaluations of the anti-microbial-biofilm, and anti-cancers bioactivities of the plant's mother liquor, i.e., aqueous-ethanolic extract, and its subsequent fractions. The in silico receptors interaction feasibility of Z. coccineum major constituents with Staph GyraseB, and human topoisomerase-IIß (h-TOP-IIß) were conducted to confirm the plant's anti-microbial and anti-cancer biological activities. Thirty-eight secondary metabolites of flavonoids, stilbene, phenolic acids, alkaloids, and coumarin classes identified by LC-ESI-TOF-MS spectrometric analysis, and tiliroside (kaempferol-3-O-(6''''-p-coumaroyl)-glucoside, 19.8%), zygophyloside-F (12.78%), zygophyloside-G (9.67%), and isorhamnetin-3-O-glucoside (4.75%) were identified as the major constituents. A superior biofilm obliteration activity established the minimum biofilm eradication concentration (MBEC) for the chloroform fraction at 3.9-15.63 µg/mL, as compared to the positive controls (15.63-31.25 µg/mL) against all the microbial strains that produced the biofilm under study, except the Aspergillus fumigatus. The aqueous-ethanolic extract showed cytotoxic effects with IC50 values at 3.47, 3.19, and 2.27 µg/mL against MCF-7, HCT-116, and HepG2 cell-lines, respectively, together with the inhibition of h-TOP-IIß with IC50 value at 45.05 ng/mL in comparison to its standard referral inhibitor (staurosporine, IC50, 135.33 ng/mL). This conclusively established the anti-cancer activity of the aqueous-ethanolic extract that also validated by in silico receptor-binding predicted energy levels and receptor-site docking feasibility of the major constituents of the plant's extract. The study helped to authenticate some of the traditional phytomedicinal properties of the anti-infectious nature of the plant.


Subject(s)
Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacology , Zygophyllum/chemistry , Biofilms/drug effects , Computer Simulation , DNA Gyrase/chemistry , DNA Topoisomerases, Type II/chemistry , Drug Evaluation, Preclinical , Drug Screening Assays, Antitumor , Gas Chromatography-Mass Spectrometry , HCT116 Cells , Hep G2 Cells , Humans , In Vitro Techniques , MCF-7 Cells , Medicine, Traditional , Mediterranean Region , Molecular Docking Simulation , Phytochemicals/chemistry , Phytochemicals/pharmacology , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plants, Medicinal/chemistry , Poly-ADP-Ribose Binding Proteins/antagonists & inhibitors , Poly-ADP-Ribose Binding Proteins/chemistry , Topoisomerase II Inhibitors/chemistry , Topoisomerase II Inhibitors/pharmacology
3.
J Med Chem ; 61(3): 1218-1230, 2018 02 08.
Article in English | MEDLINE | ID: mdl-29328649

ABSTRACT

Lead structure discovery mainly focuses on the identification of noncovalently binding ligands. Covalent linkage, however, is an essential binding mechanism for a multitude of successfully marketed drugs, although discovered by serendipity in most cases. We present a concept for the design of fragments covalently binding to proteases. Covalent linkage enables fragment binding unrelated to affinity to shallow protein binding sites and at the same time allows differentiated targeted hit verification and binding location verification through mass spectrometry. We describe a systematic and rational computational approach for the identification of covalently binding fragments from compound collections inhibiting enteroviral 3C protease, a target with high therapeutic potential. By implementing reactive groups potentially forming covalent bonds as a chemical feature in our 3D pharmacophore methodology, covalent binders were discovered by high-throughput virtual screening. We present careful experimental validation of the virtual hits using enzymatic assays and mass spectrometry unraveling a novel, previously unknown irreversible inhibition of the 3C protease by phenylthiomethyl ketone-based fragments. Subsequent synthetic optimization through fragment growing and reactivity analysis against catalytic and noncatalytic cysteines revealed specific irreversible 3C protease inhibition.


Subject(s)
Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Enterovirus/enzymology , Ketones/chemistry , Ketones/pharmacology , Viral Proteins/antagonists & inhibitors , Viral Proteins/metabolism , 3C Viral Proteases , Catalytic Domain , Cysteine Endopeptidases/chemistry , Cysteine Proteinase Inhibitors/metabolism , Drug Design , High-Throughput Screening Assays , Ketones/metabolism , Models, Molecular , Structure-Activity Relationship , Substrate Specificity , Viral Proteins/chemistry
4.
Int J Med Chem ; 2017: 7386125, 2017.
Article in English | MEDLINE | ID: mdl-29362676

ABSTRACT

Griseofulvin 1 is an important antifungal agent that has recently received attention due to its antiproliferative activity in mammalian cancer cells. Study of SAR of some griseofulvin analogues has led to the identification of 2'-benzyloxy griseofulvin 3, a more potent analogue which retards tumor growth through inhibition of centrosomal clustering. However, similar to griseofulvin 1, compound 3 exhibited poor aqueous solubility. In order to improve the poor water solubility, six new griseofulvin analogues 5-10 were synthesized and tested for their antiproliferative activity and water solubility. The semicarbazone 9 and aminoguanidine 10 analogues were the most potent against HCT116 and MCF-7 cell lines. In combination studies, compound 9 was found to exert synergistic effects with tamoxifen and 5-fluorouracil against MCF-7 and HCT116 cells proliferation, respectively. The flow cytometric analysis of effect of 9 on cell cycle progression revealed G2/M arrest in HCT116. In addition, compound 9 induced apoptosis in MCF-7 cells. Finally, all synthesized analogues revealed higher water solubility than griseofulvin 1 and benzyloxy analogue 3 in pH 1.2 and 6.8 buffer solutions.

5.
J Enzyme Inhib Med Chem ; 24(6): 1211-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19912054

ABSTRACT

Anaerobic incubation of prednisone 1 with human intestinal bacteria (HIB) afforded nine metabolites: 5beta-androst-1-ene-3,11,17-trione 3, 3alpha-hydroxy-5alpha-androstane-11,17-dione 4, 3beta,17alpha,20-trihydroxy-5alpha-pregnan-11-one 5, 3alpha,17alpha-dihydroxy-5alpha-pregnane-11,20-dione 6, 3alpha,17alpha-dihydroxy-5beta-pregnane-11,20-dione 7, 3beta,17beta-dihydroxy-5alpha-androstan-11-one 8beta, 3beta,17alpha-dihydroxy-5alpha-androstan-11-one 8alpha, 3alpha,17beta-dihydroxy-5alpha-androstan-11-one 9beta, and 3alpha,17alpha-dihydroxy-5alpha-androstan-11-one 9alpha. The structures of these metabolites (3-9) were elucidated using several spectroscopic techniques. Computer-aided prediction of potential biological activities of the isolated prednisone metabolites (3-9) revealed potential inhibition of prostaglandin E2 9-ketoreductase (PGE2 9-KR). Docking studies applied to PGE2 9-KR allowed recommendation of the metabolites 4, 8beta, and 8alpha for further pharmacological study as PGE2 9-KR inhibitors.


Subject(s)
Anti-Inflammatory Agents/metabolism , Bacteria/metabolism , Intestines/microbiology , Prednisone/metabolism , Anaerobiosis , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacokinetics , Bacteria/growth & development , Biotransformation , Computer Simulation , Humans , Hydroxyprostaglandin Dehydrogenases/antagonists & inhibitors , Hydroxyprostaglandin Dehydrogenases/metabolism , Prednisone/chemistry , Prednisone/pharmacokinetics , Spectrum Analysis
6.
Bioorg Med Chem ; 17(10): 3665-70, 2009 May 15.
Article in English | MEDLINE | ID: mdl-19398345

ABSTRACT

The discovery of the inducible isoform of cyclooxygenase enzyme (COX-2) spurred the search for anti-inflammatory agents devoid of the undesirable effects associated with classical NSAIDs. New chlorzoxazone ester prodrugs (6-8) of some acidic NSAIDs (1-3) were designed, synthesized and evaluated as mutual prodrugs with the aim of improving the therapeutic potency and retard the adverse effects of gastrointestinal origin. The structure of the synthesized mutual ester prodrugs (6-8) were confirmed by IR, (1)H NMR, mass spectroscopy (MS) and their purity was ascertained by TLC and elemental analyses. In vitro chemical stability revealed that the synthesized ester prodrugs (6-8) are chemically stable in hydrochloric acid buffer pH 1.2 as a non-enzymatic simulated gastric fluid (SGF) and in phosphate buffer pH 7.4 as non-enzymatic simulated intestinal fluid (SIF). In 80% human plasma, the mutual prodrugs were found to be susceptible to enzymatic hydrolysis at relatively faster rate (t(1/2) approximately 37 and 34 min for prodrugs 6 and 7, respectively). Mutual ester prodrugs (6-8) were evaluated for their anti-inflammatory and muscle relaxation activities. Scanning electromicrographs of the stomach showed that the ester prodrugs induced very little irritancy in the gastric mucosa of rats after oral administration for 4days. In addition, docking of the mutual ester prodrugs (6-8) into COX-2 active site was conducted in order to predict the affinity and orientation of these prodrugs at the enzyme active site.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Carboxylic Acids/chemistry , Chlorzoxazone/analogs & derivatives , Chlorzoxazone/pharmacology , Prodrugs/pharmacology , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Carboxylic Acids/chemical synthesis , Catalytic Domain , Chlorzoxazone/chemical synthesis , Chlorzoxazone/chemistry , Computer Simulation , Cyclooxygenase 2/chemistry , Cyclooxygenase 2/metabolism , Drug Design , Drug Stability , Esters/chemical synthesis , Esters/chemistry , Esters/pharmacology , Male , Prodrugs/chemical synthesis , Prodrugs/chemistry , Rats , Rats, Wistar , Structure-Activity Relationship
7.
J Enzyme Inhib Med Chem ; 24(3): 722-9, 2009 Jun.
Article in English | MEDLINE | ID: mdl-18720193

ABSTRACT

A linear quantitative structure-activity relationship (QSAR) study that encodes various aspects of physicochemical, topological and electronic descriptors has been developed for a series of 1,3,4-thiadiazole-2-thione derivatives (1a-r and 2a-c). The carbonic anhydrase IX inhibitory activity of the candidates under study (1a-r and 2a-c) were correlated to the selected parameters using stepwise linear regression analyses to achieve the best QSAR model. Promising results were obtained with the employed tetra-parametric model indicating that the information approach used in the present investigation is quite useful for modeling carbonic anhydrase IX inhibitors.


Subject(s)
Antigens, Neoplasm/metabolism , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Neoplasms/drug therapy , Neoplasms/enzymology , Quantitative Structure-Activity Relationship , Thiadiazoles/therapeutic use , Thiones/therapeutic use , Algorithms , Biomarkers, Tumor , Carbonic Anhydrase IX , Carbonic Anhydrase Inhibitors/therapeutic use , Humans , Inhibitory Concentration 50 , Linear Models , Molecular Structure , Neoplasms/metabolism , Neoplasms/pathology , Thiadiazoles/chemistry , Thiadiazoles/pharmacology , Thiones/chemistry , Thiones/pharmacology
8.
Bioorg Med Chem ; 16(17): 7983-91, 2008 Sep 01.
Article in English | MEDLINE | ID: mdl-18693017

ABSTRACT

In trials to preserve the pharmacological profile and improve the bioavailability via lipophilicity increment of baclofen 1 and searching for more potent and less toxic muscle relaxants and analgesics, nine substituted cyclic analogues of 1 were designed and synthesized. The target derivatives 5-(4-chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one (11-19) were obtained through amide formation to the corresponding intermediates (2-10) followed by cyclization using acetic anhydride. The structures of the target compounds (11-19) were confirmed by IR, (1)H NMR, MS, and elemental analyses. The neuropharmacological activities of these lipophilic cyclic analogues (11-19) were assessed for their effects on motor activity, muscle relaxation, pain relief and impaired cognition, by intraperitoneal administration at a dose of 3mg/kg with reference to those of baclofen 1. Our results showed that compounds 11-14 are devoid of all of the tested pharmacological effects associated with 1. In all paradigms tested, undecyl, tridecyl, heptdec-8-enyl and benzyl substituted analogue derivatives (15, 16, 18, and 19) revealed a significant neurological activity being vividly favorable comparable with baclofen 1. 2-Benzyl-5-(4-chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivative 19 is the most active candidate with high significant neurological potencies, while 5-(4-chlorophenyl)-2-(dec-8-enyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivative 17 displayed activity at relatively higher time interval. These results probe a new structurally distinct class incorporating 1,3-oxazepine nucleus as promising candidates as GABA(B) agonists for further investigations.


Subject(s)
Baclofen/chemistry , Cognition Disorders/drug therapy , Drug Design , Muscle Relaxation/drug effects , Oxazepines/chemical synthesis , Oxazepines/pharmacology , Pain/drug therapy , Animals , Baclofen/pharmacology , Cyclization , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , GABA Agonists/chemical synthesis , GABA Agonists/chemistry , GABA Agonists/pharmacology , GABA-B Receptor Agonists , Hydrophobic and Hydrophilic Interactions , Injections, Intraperitoneal , Magnetic Resonance Spectroscopy/methods , Magnetic Resonance Spectroscopy/standards , Male , Mice , Molecular Structure , Motor Activity/drug effects , Oxazepines/chemistry , Receptors, GABA-B/chemistry , Reference Standards , Stereoisomerism
9.
Bioorg Med Chem ; 15(22): 6975-84, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17822907

ABSTRACT

A new series of 1,3,4-thiadiazole-2-thione derivatives have been prepared and assayed for the inhibition of three physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isozymes, the cytosolic human isozymes I and II, and the transmembrane, tumor-associated hCA IX. Against hCA I the investigated thiones, showed inhibition constants in the range of 2.55-222 microM, against hCA II in the range of 2.0-433 microM, and against hCA IX in the range of 1.25-148 microM. Compound 5c, 4-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-1-(5-nitro-2-oxoindolin-3-ylidene)semicarbazide showed interesting inhibition of the tumor-associated hCA IX with K(I) value of 1.25 microM, being the first non-sulfonamide type inhibitor of such activity. This result is rather important taking into consideration the known antitumor activity of thiones. In addition, docking of the tested compounds into CA II active site was performed in order to predict the affinity and orientation of these compounds at the isozyme active site. The results showed similar orientation of the target compounds at CA II active site compared with reported sulfonamide type CAIs with the thione group acting as a zinc-binding moiety.


Subject(s)
Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase IV/antagonists & inhibitors , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrase Inhibitors/chemistry , Crystallography, X-Ray , Drug Design , Humans , Ligands , Models, Molecular , Molecular Structure , Protein Structure, Tertiary , Structure-Activity Relationship , Thiadiazoles/chemical synthesis , Thiadiazoles/chemistry , Thiadiazoles/pharmacology , Thiones/chemical synthesis , Thiones/chemistry , Thiones/pharmacology
10.
Arzneimittelforschung ; 52(11): 833-9, 2002.
Article in English | MEDLINE | ID: mdl-12489255

ABSTRACT

In a one pot procedure, 18 compounds of 7-(substituted phenyl)-2-substituted-6,7-dihydro-4H-[1,2,4]triazolo[1,5-a] pyrimidin-5-one derivatives (16-33) have been synthesized. 3(5)-Amino-5(3)-substituted-1,2,4-triazole derivatives (7-12) were used as synthomes which were cyclo-condensed by fusion with substituted methyl cinnamate esters (13-15) to afford the target compounds (16-33). In an effort to develop new non-nucleoside antiviral agents, compounds 16-33 were evaluated for their anti-HIV-1 and anti-HSV-1 activities. Complete inhibition of the proliferation of HIV-1 viruses was achieved by compounds 22, 23 and 24 at concentrations of 25, 25 and 50 micrograms/ml, respectively. 7-Phenyl-2-(n-pentyl)-6,7-dihydro-4H-[1,2,4]triazolo[1,5-a]pyrimidin-5-one (19) exhibited potential activity against HSV-1 with 88% reduction in the viral plaques. The suggested marked specificity of this class of compounds as anti-HIV-1 and HSV-1 agents is discussed.


Subject(s)
Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/pharmacology , Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , HIV-1/drug effects , Herpesvirus 1, Human/drug effects , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Cell Line , Crystallization , Humans , Indicators and Reagents , Magnetic Resonance Spectroscopy , Solvents , Spectrophotometry, Infrared , Viral Plaque Assay
SELECTION OF CITATIONS
SEARCH DETAIL
...